Home › Research › Drug development
Conference report: dementia research and care and its impact in Switzerland
Leyhe T, Jucker M, Nef T, Sollberger M, Riese F, Haba-Rubio J, Verloo H, Lüthi R et al.. Swiss medical weekly, 2020-11-01
Topic: Risk, prevention and care in population studies
Plain-language summary
In October 2019, a Swiss panel of experts met for the Dementia Summit in Brunnen, Switzerland, to discuss the latest scientific findings on basic and clinical research, as well as practical and political approaches to the challenges of dementia disorders in Switzerland. To study pathophysiological changes, as well as the underlying mechanism of fluid biomarker changes, excellent experimental approaches, including transgenic mouse models, are available. Current knowledge about presymptomatic disease progression is largely derived from the longitudinal study of individuals with autosomal dominant mutations (Dominantly Inherited Alzheimer Network).
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This conference report describes experimental approaches including transgenic mouse models for studying pathophysiological changes and fluid biomarker changes in dementia. It notes that more than one third of identified dementia risk factors can be modified.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Leyhe, T., Jucker, M., Nef, T., Sollberger, M., Riese, F., Haba-Rubio, J., et al. (2020). Conference report: dementia research and care and its impact in Switzerland. Swiss medical weekly. https://doi.org/10.4414/smw.2020.20376
Vancouver
Leyhe T, Jucker M, Nef T, Sollberger M, Riese F, Haba-Rubio J, et al. Conference report: dementia research and care and its impact in Switzerland. Swiss medical weekly. 2020. doi:10.4414/smw.2020.20376. PMID: 33277912.
BibTeX
@article{leyhe2020-33277912,
author = {Leyhe, T. and Jucker, M. and Nef, T. and Sollberger, M. and Riese, F. and Haba-Rubio, J. and Verloo, H. and Lüthi, R. and others},
title = {{Conference report: dementia research and care and its impact in Switzerland}},
journal = {Swiss medical weekly},
year = {2020},
doi = {10.4414/smw.2020.20376},
pmid = {33277912},
url = {https://doi.org/10.4414/smw.2020.20376}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- To study pathophysiological changes, as well as the underlying mechanism of fluid biomarker changes, excellent experimental approaches, including transgenic mouse models, are available.
- Current knowledge about presymptomatic disease progression is largely derived from the longitudinal study of individuals with autosomal dominant mutations (Dominantly Inherited Alzheimer Network).
- Importantly, more than one third of identified dementia risk factors can be modified.
- For example, sleep disturbances are not only associated with dementia and neurodegeneration in specific brain regions, but also precede cognitive decline and contribute to the development of brain pathology.
Why it matters
This conference report describes experimental approaches including transgenic mouse models for studying pathophysiological changes and fluid biomarker changes in dementia. It notes that more than one third of identified dementia risk factors can be modified.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 43/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Swiss medical weekly) |
| Journal's citation record | 1 / 4 | Swiss Medical Weekly: journal h-index 95 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.8 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Julius Popp: h-index 59 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Zurich: institution h-index 1,220 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 13 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33277912) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.4414/smw.2020.20376
- PubMed: 33277912
- Original source →
- Free full text: Swiss Medical Weekly →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Drug development from nearby years
Also tagged “prevalence”
1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.